All In Biotech

Drug Trial Radar · NCT07823608

A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Use a Breathing Machine (PAP) (VESPER-OSA 1)

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE-MONTHLY BEROBENATIDE IN ADULTS WITH OBSTRUCTIVE SLEEP APNEA AND OVERWEIGHT OR OBESITY RECEIVING POSITIVE AIRWAY PRESSURE THERAPY (VESPER-OSA 1)

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 258 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

258

Planned (sponsor's estimate)

Start

Sep 17, 2026

Primary completion

Apr 30, 2028

Study completion Jun 18, 2028

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Sep 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being done to learn about the safety and effects of a study medicine called berobenatide (bear-oh-BEN-uh-tide). The study will see if berobenatide can help adults with breathing problems during sleep (obstructive sleep apnea \[OSA\]) and overweight or obesity who use a breathing machine (positive airway pressure \[PAP\] machine). People may be able to take part if they are adults with moderate to severe OSA, have overweight or obesity, and have been using PAP therapy before joining the study. Participants will be assigned by chance to receive either berobenatide or a placebo (a treatment that looks like the study medicine but contains no active medicine). The study treatment will be given as an injection under the skin approximately once a month. Participants will receive study treatment at study sites and may administer some doses at home after receiving training. During the study, participants will attend study visits, undergo sleep studies, complete questionnaires, and have health assessments performed. Researchers will compare the effects of berobenatide and placebo on sleep apnea, body weight, and other health measures.

Conditions

  • Apnea
  • Sleep Disorders
  • Overweight and/or Obesity

Interventions

  • BerobenatideDrug

    By Subcutaneous Injection

  • PlaceboOther

    By Subcutaneous Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Apnea-Hypopnea Index (AHI)Time frame: baseline, Week 52

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Cullman Clinical Trials

    Cullman, Alabama · Recruiting

  • Preferred Research Partners, Inc.

    Little Rock, Arkansas · Recruiting

  • Probe Clinical Research Corporation

    Riverside, California · Recruiting

  • DM Clinical Research

    Bradenton, Florida · Recruiting

  • Revive Research Institute, Inc.

    Southfield, Michigan · Not yet recruiting

  • Headlands Research - Twin Cities

    Maplewood, Minnesota · Recruiting

  • Velocity Clinical Research, Dallas

    Dallas, Texas · Recruiting

  • DM Clinical Research

    Tomball, Texas · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.